Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00988637 · ClinicalTrials.gov registry record · Phase 4
Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 138
- Enrollment target
NCT00988637 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 138 participants.
The verdict
NCT00988637, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 138 participants
- Enrollment target
Study Summary
This clinical trial will evaluate the efficacy and safety of Clobex® (clobetasol propionate) Spray 0.05% and Vectical™ (calcitriol) Ointment 3 µg/g over a four week period of use in one of two different regimens: 1. Vectical™ Ointment treatment, twice daily on weekdays (Mon - Fri) and Clobex® Spray treatment twice daily on weekends (Sat - Sun) for 28 days 2. Clobex® Spray once each morning and Vectical™ Ointment once each evening for 28 days
Interventions
- DRUG Vectical™ Ointment weekdays and Clobex® Spray weekends regimen
- DRUG Clobex® Spray morning and Vectical™ Ointment evening regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00988637
The ClinicalTrials.gov registry entry for NCT00988637 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vectical™ Ointment weekdays and Clobex® Spray weekends regimen is the first listed.
NCT00988637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00988637 about?
NCT00988637 is a clinical study titled "Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis". This clinical trial will evaluate the efficacy and safety of Clobex® (clobetasol propionate) Spray 0.05% and Vectical™ (calcitriol) Ointment 3 µg/g over a four week period of use in one of two different regimens: 1. Vectical™ Ointment treatment, twice daily on weekdays (Mon - Fri) and Clobex® Spray...
What is the current status of trial NCT00988637?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 138 participants. The study started on 2009-10. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00988637?
The interventions under investigation include: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen (DRUG), Clobex® Spray morning and Vectical™ Ointment evening regimen (DRUG).
Who is sponsoring clinical trial NCT00988637?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.